Enhancement Without Contrast: Stability-Aware Multicenter Machine Learning for Glioma MRI Imaging
This addresses safety and accessibility issues in glioma imaging for patients and clinicians, though it is incremental as it focuses on model selection rather than a new prediction method.
The study tackled the problem of predicting contrast enhancement in glioma MRI from non-contrast images to reduce reliance on gadolinium-based agents, achieving an average external testing accuracy of 0.93 across multiple datasets.
Gadolinium-based contrast agents (GBCAs) are central to glioma imaging but raise safety, cost, and accessibility concerns. Predicting contrast enhancement from non-contrast MRI using machine learning (ML) offers a safer alternative, as enhancement reflects tumor aggressiveness and informs treatment planning. Yet scanner and cohort variability hinder robust model selection. We propose a stability-aware framework to identify reproducible ML pipelines for multicenter prediction of glioma MRI contrast enhancement. We analyzed 1,446 glioma cases from four TCIA datasets (UCSF-PDGM, UPENN-GB, BRATS-Africa, BRATS-TCGA-LGG). Non-contrast T1WI served as input, with enhancement derived from paired post-contrast T1WI. Using PyRadiomics under IBSI standards, 108 features were extracted and combined with 48 dimensionality reduction methods and 25 classifiers, yielding 1,200 pipelines. Rotational validation was trained on three datasets and tested on the fourth. Cross-validation prediction accuracies ranged from 0.91 to 0.96, with external testing achieving 0.87 (UCSF-PDGM), 0.98 (UPENN-GB), and 0.95 (BRATS-Africa), with an average of 0.93. F1, precision, and recall were stable (0.87 to 0.96), while ROC-AUC varied more widely (0.50 to 0.82), reflecting cohort heterogeneity. The MI linked with ETr pipeline consistently ranked highest, balancing accuracy and stability. This framework demonstrates that stability-aware model selection enables reliable prediction of contrast enhancement from non-contrast glioma MRI, reducing reliance on GBCAs and improving generalizability across centers. It provides a scalable template for reproducible ML in neuro-oncology and beyond.